US Patent

US11603363 — Crystalline form of LNP023

Composition of Matter · Assigned to Novartis AG · Expires 2041-05-25 · 15y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a crystalline hydrate form of IPTACOPAN HYDROCHLORIDE and a process for its preparation, as well as a pharmaceutical composition containing it.

USPTO Abstract

Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.

Drugs covered by this patent

Patent Metadata

Patent number
US11603363
Jurisdiction
US
Classification
Composition of Matter
Expires
2041-05-25
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.